Premium
Elevated serum thymus and activation‐regulated chemokine ( TARC / CCL 17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms ( DRESS )/drug‐induced hypersensitivity syndrome ( DIHS )
Author(s) -
Ogawa K.,
Morito H.,
Hasegawa A.,
Miyagawa F.,
Kobayashi N.,
Watanabe H.,
Sueki H.,
Tohyama M.,
Hashimoto K.,
Kano Y.,
Shiohara T.,
Ito K.,
Fujita H.,
Aihara M.,
Asada H.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12948
Subject(s) - medicine , dermatology
1 Kauzman A, Quesnel-Mercier A, Lalonde B. Orofacial granulomatosis: 2 case reports and literature review. J Can Dent Assoc 2006; 72:325–9. 2 Campbell HE, Escudiet MP, Patel P et al. Review article: cinnamonand benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther 2011; 34:687–701. 3 Giovannetti A, Mazzetta F, Cavani A et al. Skewed T-cell receptor variable b repertoire and massive T-cell activation in idiopathic orofacial granulomatosis. Int J Immunopathol Pharmacol 2012; 25:503– 11. 4 Al Johani KA, Moles DR, Hodgson TA et al. Orofacial granulomatosis: clinical features and long-term outcome of therapy. J Am Acad Dermatol 2010; 62:611–20. 5 McCartan BE, Healy CM, McCreary CE et al. Characteristics of patients with orofacial granulomatosis. Oral Dis 2011; 17:696– 704. 6 O’Neill ID, Scully C. Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis. Oral Dis 2012; 18:633– 8. 7 Elliott T, Campbell H, Escudier M et al. Experience with anti-TNFa therapy for orofacial granulomatosis. J Oral Pathol Med 2011; 40:14–19. 8 Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn’s disease and orofacial granulomatosis. Oral Surg Oral Med Pathol Oral Radiol Endod 2003; 95:578–85. Funding sources: none.